At the news
? MIXEDIMPACT 6/10 8-K filed Jul 31, 2026 at 08:30 ET
Karyopharm announced Phase 3 XPORT-EC-042 trial failure for selinexor in endometrial cancer (PFS p=0.0791, not significant), while simultaneously disclosing plans to submit an sNDA for selinexor in myelofibrosis in August 2026 under accelerated approval, though the FDA has requested further discussion on supporting data. The company is also exploring financing and strategic alternatives with Centerview Partners to extend its cash runway, signaling financial pressure.
- Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer failed to meet primary endpoint of PFS (HR=0.76, p=0.0791, not statistically significant)
- Company plans to submit sNDA for selinexor + ruxolitinib in myelofibrosis in August 2026 under accelerated approval pathway
- FDA provided written feedback that SVR35 qualifies as a surrogate endpoint but requires further discussion on data to support sNDA and conversion to traditional approval
- Company exploring financing transactions and strategic alternatives with Centerview Partners to extend cash runway; no assurance of any transaction
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access